80.36
-2.26 (-2.74%)
| Previous Close | 82.62 |
| Open | 82.73 |
| Volume | 1,406,552 |
| Avg. Volume (3M) | 2,606,406 |
| Market Cap | 10,910,524,416 |
| Price / Sales | 94.71 |
| Price / Book | 60.31 |
| 52 Weeks Range |
| Operating Margin (TTM) | -9,856.30% |
| Diluted EPS (TTM) | -5.29 |
| Quarterly Revenue Growth (YOY) | 89.10% |
| Total Debt/Equity (MRQ) | 727.94% |
| Current Ratio (MRQ) | 5.99 |
| Operating Cash Flow (TTM) | -398.00 M |
| Levered Free Cash Flow (TTM) | -241.41 M |
| Return on Assets (TTM) | -34.12% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Cytokinetics, Incorporated | Mixed | Bullish |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | 0.0 |
| Price Volatility | -0.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 2.5 |
| Average | 0.50 |
|
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary disease. The company's product, named as MYQORZO, is an allosteric and reversible inhibitor of cardiac myosin motor activity. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 0.72% |
| % Held by Institutions | 119.58% |
No data within this time range.
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| BLUM ROBERT I | - | 82.24 | -7,500 | -616,800 |
| DALY JAMES M | 82.62 | - | 151 | 12,476 |
| HARRINGTON ROBERT ARTHUR | 82.62 | - | 151 | 12,476 |
| HENDERSON JOHN T | 82.62 | - | 272 | 22,473 |
| KAYE EDWARD M. MD | 82.62 | - | 151 | 12,476 |
| MALIK FADY IBRAHAM | - | 85.56 | -3,500 | -299,460 |
| WIERENGA WENDELL | 82.62 | - | 75 | 6,197 |
| WYSENSKI NANCY | 82.62 | - | 75 | 6,197 |
| Aggregate Net Quantity | -10,125 | |||
| Aggregate Net Value ($) | -843,968 | |||
| Aggregate Avg. Buy ($) | 82.62 | |||
| Aggregate Avg. Sell ($) | 83.90 | |||
| Insider Range ($) | ||||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| DALY JAMES M | Director | 15 Jul 2026 | Acquired (+) | 151 | 82.62 | 12,476 |
| HARRINGTON ROBERT ARTHUR | Director | 15 Jul 2026 | Acquired (+) | 151 | 82.62 | 12,476 |
| HENDERSON JOHN T | Director | 15 Jul 2026 | Acquired (+) | 272 | 82.62 | 22,473 |
| KAYE EDWARD M. MD | Director | 15 Jul 2026 | Acquired (+) | 151 | 82.62 | 12,476 |
| WIERENGA WENDELL | Director | 15 Jul 2026 | Acquired (+) | 75 | 82.62 | 6,197 |
| WYSENSKI NANCY | Director | 15 Jul 2026 | Acquired (+) | 75 | 82.62 | 6,197 |
| BLUM ROBERT I | Officer | 13 Jul 2026 | Sell (-) | 7,500 | 82.24 | 616,800 |
| BLUM ROBERT I | Officer | 13 Jul 2026 | Option execute | 7,490 | - | - |
| MALIK FADY IBRAHAM | Officer | 07 Jul 2026 | Sell (-) | 3,500 | 85.56 | 299,460 |
| MALIK FADY IBRAHAM | Officer | 07 Jul 2026 | Option execute | 3,500 | - | - |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |